Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
Boehringer pens $1B pact to reduce eye drug injections
Boehringer Ingelheim is continuing to explore its newfound interest in eye health, penning a $1 billion biobucks pact with Re-Vana Therapeutics.
James Waldron
Jul 28, 2025 8:48am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
Transpire licenses PDE4 inhibitor for lung disease
Jun 3, 2025 9:45am
PureTech's deupirfenidone shows durable effect in IPF study
May 20, 2025 5:15pm
Boehringer's phase 3 lung data get muted response from analysts
May 19, 2025 9:24am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
